It can be beneficial to make use of more sophisticated imaging assays to assess a drug’s mechanism of action, to find efficacy signals within sparse data or to address questions related to treatment-specific effects.
TORONTO (PRWEB)
October 13, 2021
The majority of imaging studies conducted during the course of oncology clinical trials consist of standard clinical examinations — CT scans, bone scans, brain scans, etc. However, in some cases it can be beneficial to make use of more sophisticated imaging assays to assess a drug’s mechanism of action, to find efficacy signals within sparse data or to address questions related to treatment-specific effects.
This talk will discuss some of these techniques and their applications, including:
-
Perfusion imaging - Diffusion imaging
- Molecular imaging
- Multi-modality imaging
This webinar is part of a series on Imaging in Oncology.
Join Edward Ashton, PhD, VP, Oncology Imaging, Philips BioTel Research, for Part 1 of the live webinar series on Tuesday, November 2, 2021 at 1pm EDT.
Click here for Part 2: Assessing Imaging Outcomes in Immune Oncology (upcoming on Nov 3/21)
Click here for Part 3: Deep Learning for Image Analysis (upcoming on Nov 8/21)
For more information, or to register for this event, visit Advanced Imaging in Oncology Clinical Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Share article on social media or email: